Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Saliva 8-Hydroxy-2'-Deoxyguanosine Changes Following Radiotherapy in Patients With Head and Neck Cancer Publisher



Abassi F1 ; Mirzaiidizgah I2 ; Manifar S3 ; Kazemian A4 ; Khatami R1 ; Nazarisharbayani F5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Oral Medicine, School of Dentistry, Shahed University, Tehran, Iran
  2. 2. Department of Physiology, School of Medicine, Aja University of Medical Science, Tehran, Iran
  3. 3. Department of Oral Medicine, School of Dentistry, Tehran University of Medical Science, Tehran, Iran
  4. 4. Department School of Medical, Tehran University of Medical Science, Tehran, Iran
  5. 5. Department of Endodontics, School of Dentistry, Kerman University of Medical Sciences, Kerman, Iran

Source: Dental Cadmos Published:2016


Abstract

OBJECTIVES. Radiotherapy is the most common treatment in patients suffering from head and neck cancers. The aim of this study was to evaluate the changes in 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels-As a crucial biomarker of oxidative stress and carcinogenesis-in patients affected with head and neck squamous cell carcinoma (HNSCC) following radiotherapy. MATERIALS AND METHODS. A cross-sectional study was carried out in 30 patients with HNSCC before and after radiotherapy, and in 30 healthy controls. The HNSCC were documented by two blinded expert pathologists. Whole saliva samples were collected and 8-OHdG levels were analysed by ELISA method. RESULTS. The saliva levels of 8-OHdG (ng/ mL) were significantly higher in patients with HNSCC before radiotherapy (502.2 ± 48.0) than after radiotherapy (311.2 ± 44.1) and control individuals (326.7 ± 41.0) (p < 0.05). There was no significant difference in saliva 8-OHdG between patients with HNSCC after radiotherapy and control individuals. CONCLUSIONS. It seems that saliva 8-OHdG levels return to normal range after radiotherapy in patients with HNSCC. ©2016 EDRA SpA.